• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • About ALS
    • Understanding the Science
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • ALS Awareness Month:
      Behind the Breakthrough
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

RELENTLESS PROGRESS.

Founded by Dan Doctoroff in 2013, Target ALS is dedicated to breaking down barriers to research in the fight against amyotrophic lateral sclerosis (ALS). Through our landmark Innovation Ecosystem, we are accelerating the discovery of effective treatments.

OUR MISSION.

Our mission is to break down barriers to ALS research to find effective treatments. By uniting academia, the pharma and biotech industry, government, venture capital, related nonprofits, and the ALS community, we aim to overcome the challenges that have long hindered progress, bringing hope and tangible advancements to those affected by this devastating disease.

OUR VISION.

Our vision is a world where Everyone Lives, where breakthroughs in ALS research lead to effective treatments that give those living with ALS and their families the hope and future they deserve.

OUR VALUES.

Impatient Optimism.

We are driven by the urgency of ALS, knowing that those diagnosed often have only 2-5 years to live. This fuels our impatience for breakthroughs, yet we remain steadfastly optimistic that effective treatments are within reach.

Deliberate Disruption.

We challenge the status quo at every level by uniting multidisciplinary teams, removing intellectual property restrictions, and providing minimal to no-cost resources worldwide with no strings attached. We harness cutting-edge technology, make data-driven decisions, and foster unconventional partnerships across academia, industry, and nonprofits. By streamlining processes, supporting the best ideas, and addressing overlooked needs, we’re redefining what’s possible in ALS research and creating a global impact.

Radical Collaboration.

We bring together diverse voices—researchers, clinicians, industry leaders, and advocates—to foster partnerships that amplify impact and drive meaningful results. Transparency, inclusivity, and shared learning are at the heart of everything we do.

OUR FOUNDER.

Dan Doctoroff, the founder of Target ALS, is a visionary leader with a deeply personal connection to the fight against amyotrophic lateral sclerosis (ALS). Diagnosed with the disease in 2021, Dan’s commitment to accelerating ALS research stems from both his diagnosis and his family’s history with the disease, as his father and uncle also battled ALS. Before founding Target ALS in 2013, Dan’s career spanned influential roles, including serving as the Deputy Mayor for Economic Development and Rebuilding for New York City and CEO of Bloomberg LP. His drive to break down barriers and foster innovation is the foundation of Target ALS’s mission, ensuring that collaboration, optimism, and urgency guide the search for effective treatments.

LEARN MORE.

OUR TEAM.

At Target ALS, we bring together a dedicated team of experts, advisors, and leaders committed to transforming the landscape of ALS research. Our staff combines deep expertise in clinical research, science, business, and philanthropy to drive innovative collaborations and groundbreaking initiatives. Our Board of Directors, made up of prominent leaders from various industries, provides strategic guidance to amplify our impact. Ensuring the highest standards, our Independent Review Committee (IRC) evaluates the scientific rigor and effectiveness of our research efforts, while our Conflict of Interest (COI) Committee safeguards transparency and integrity in every partnership.

LEARN MORE

RESOURCES.

We empower scientists and researchers with access to essential tools and resources designed to break down barriers in ALS research. Through our Research Cores, we provide human postmortem tissue, multi-omic datasets, stem cell lines, biofluids, reagents, and more—all without intellectual property restrictions and minimal to no cost.

LEARN MORE

FINANCIALS.

At Target ALS, we uphold the highest standards of financial responsibility and transparency. We openly share our audited financial statements and annual reports, detailing our financial activities and the impact of your contributions. This commitment ensures that your donations effectively drive our mission to eliminate barriers in ALS research and develop effective treatments.

LEARN MORE

STRATEGY.

Our Innovation Ecosystem, launched in 2013, is powered by six reinforcing strategies to accelerate research from the bench to the bedside:

  • Collaborative funding opportunities break silos and foster partnership
  • Accessible tools and resources empower ideas from researchers across disciplines
  • Engagement of pharma/biotech industry accelerates drug development
  • Independent grant review ensures all ideas get fair and transparent evaluation
  • No intellectual property restrictions on science galvanizes innovation
  • Networking forges collaborations among the worldwide research community

LEARN MORE

IMPACT.

675+

Research Grants
We’ve Funded

$80.4M

The Amount We’ve
Invested in ALS Research

56%

Of Our Funded Consortia
Have Led to Drug
Discovery Programs

8

Clinical Trials Have
Emerged From
Our Funded Work

1641

Academic and Industry
Users Utilizing our
Research Cores

14

Active Global Research
Sites Enrolling Participants

Join the Target ALS Email List

Name(Required)
Interests(Required)
Mark the options that best describe your interest in ALS

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting

Join us this ALS Awareness Month to discover the people, stories, and science accelerating progress in ALS research.

Name(Required)
Interests(Required)
Mark the options that best describe your interest in ALS